Anti-Rheumatic Drugs - Burundi

Burundi

The Anti-Rheumatic Drugs market in Burundi is expected to see a significant increase in revenue.
By 2024, the projected revenue is estimated to reach US$0.46m.
This indicates a positive growth trend in the market.
Furthermore, it is expected that the market will continue to grow at an annual rate of 1.68% from 2024 to 2029.
By the end of 2029, the market volume is projected to reach US$0.50m.
When comparing the revenue generated in Burundi to other countries globally, it is worth noting that United States will be the highest revenue generator.
In 2024 alone, United States is expected to generate a significant revenue of US$34,700.00m in the Anti-Rheumatic Drugs market.
This showcases the dominance of the United States in this particular market.
Burundi's market for anti-rheumatic drugs is experiencing a surge in demand due to an increase in the prevalence of rheumatic diseases among the population.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Rheumatic Drugs market in Burundi has seen a steady growth in recent years.

Customer preferences: The demand for Anti-Rheumatic Drugs in Burundi is mainly driven by the increasing prevalence of rheumatic diseases in the country. According to the World Health Organization, rheumatic diseases affect a significant proportion of the population in Burundi. Patients suffering from these diseases require long-term treatment with Anti-Rheumatic Drugs to manage their symptoms and improve their quality of life.

Trends in the market: The Anti-Rheumatic Drugs market in Burundi is dominated by generic drugs due to their affordability and availability. The market has seen an increase in the number of local pharmaceutical companies that manufacture and distribute generic Anti-Rheumatic Drugs. These companies have been able to capture a significant market share by offering low-cost alternatives to the branded drugs.

Local special circumstances: Burundi is a low-income country with a limited healthcare budget. The government's spending on healthcare is low, and patients often have to pay out of pocket for their treatment. This has led to a preference for generic drugs, which are more affordable than branded drugs. Additionally, the country has a weak regulatory framework, which has resulted in the proliferation of substandard and counterfeit drugs in the market.

Underlying macroeconomic factors: The Burundian economy is heavily dependent on agriculture, which accounts for more than 80% of the country's exports. The country's GDP per capita is one of the lowest in the world, and the healthcare sector is underfunded. The lack of investment in healthcare infrastructure and the shortage of healthcare professionals have resulted in a limited capacity to diagnose and treat rheumatic diseases. The country also faces political instability, which has led to a decline in foreign investment and donor funding. In conclusion, the Anti-Rheumatic Drugs market in Burundi is driven by the increasing prevalence of rheumatic diseases in the country. The market is dominated by generic drugs due to their affordability and availability. However, the market is also plagued by substandard and counterfeit drugs due to the weak regulatory framework. The limited healthcare budget and the shortage of healthcare professionals pose significant challenges to the diagnosis and treatment of rheumatic diseases in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.